PE20021008A1 - Composiciones para vacuna antibacteriana - Google Patents

Composiciones para vacuna antibacteriana

Info

Publication number
PE20021008A1
PE20021008A1 PE2002000160A PE2002000160A PE20021008A1 PE 20021008 A1 PE20021008 A1 PE 20021008A1 PE 2002000160 A PE2002000160 A PE 2002000160A PE 2002000160 A PE2002000160 A PE 2002000160A PE 20021008 A1 PE20021008 A1 PE 20021008A1
Authority
PE
Peru
Prior art keywords
bacteria
gene
mutation
refers
represented
Prior art date
Application number
PE2002000160A
Other languages
English (en)
Spanish (es)
Inventor
Troy E Fuller
David E Lowery
Michael J Kennedy
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20021008A1 publication Critical patent/PE20021008A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PE2002000160A 2001-03-15 2002-02-27 Composiciones para vacuna antibacteriana PE20021008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
PE20021008A1 true PE20021008A1 (es) 2002-11-13

Family

ID=25201919

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000160A PE20021008A1 (es) 2001-03-15 2002-02-27 Composiciones para vacuna antibacteriana

Country Status (18)

Country Link
US (2) US6790950B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368456B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005502315A (cg-RX-API-DMAC7.html)
AR (2) AR035745A1 (cg-RX-API-DMAC7.html)
AT (1) ATE500316T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002240033B2 (cg-RX-API-DMAC7.html)
CA (2) CA2438315C (cg-RX-API-DMAC7.html)
CY (1) CY1112014T1 (cg-RX-API-DMAC7.html)
DE (1) DE60239318D1 (cg-RX-API-DMAC7.html)
DK (1) DK1368456T3 (cg-RX-API-DMAC7.html)
ES (1) ES2362041T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008296A (cg-RX-API-DMAC7.html)
NZ (1) NZ528208A (cg-RX-API-DMAC7.html)
PE (1) PE20021008A1 (cg-RX-API-DMAC7.html)
PT (1) PT1368456E (cg-RX-API-DMAC7.html)
SI (1) SI1368456T1 (cg-RX-API-DMAC7.html)
TW (4) TWI334884B (cg-RX-API-DMAC7.html)
WO (1) WO2002075507A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP2010505831A (ja) * 2006-10-05 2010-02-25 ニューヨーク ブラッド センター， インコーポレイテッド 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
WO2010002989A2 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015066292A1 (en) * 2013-11-01 2015-05-07 Merial Limited Attenuated pasteurella multocidavaccines & methods of making & use thereof
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
HU219535B (hu) 1991-03-05 2001-05-28 Wellcome Foundation Ltd. Rekombináns proteineket expresszáló, attenuált baktériumokat tartalmazó vakcinák
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
AU5591694A (en) 1992-11-06 1994-06-08 Regents Of The University Of Minnesota Composition protective against (p. multocida) pasteurellosis infection
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
AU1662595A (en) 1994-01-28 1995-08-15 Herbert Altmann Method of determining the activity of a regulatory factor, and use of the method
RU2370541C2 (ru) 1994-12-09 2009-10-20 Имерджент Продакт Дивелопмент Юк Лимитед Vgc2 днк salmonella typhimurium, мутантная бактерия, обладающая пониженной способностью к адаптации к условиям окружающей среды, и способ ее получения
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
EP0939830B1 (en) * 1996-09-06 2008-12-31 Peter Ruhdal Jensen A method of improving the production of a desired product from a cell
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase
AU2001258373A1 (en) * 2000-04-27 2001-11-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
JP2011097938A (ja) 2011-05-19
CY1112014T1 (el) 2015-11-04
EP1368456B1 (en) 2011-03-02
US7476391B2 (en) 2009-01-13
WO2002075507B1 (en) 2003-12-11
AR035745A1 (es) 2004-07-07
SI1368456T1 (sl) 2011-06-30
DK1368456T3 (da) 2011-05-23
JP2005502315A (ja) 2005-01-27
AR071888A2 (es) 2010-07-21
TW201040261A (en) 2010-11-16
WO2002075507A2 (en) 2002-09-26
PT1368456E (pt) 2011-06-01
MXPA03008296A (es) 2007-05-28
DE60239318D1 (de) 2011-04-14
TWI335935B (en) 2011-01-11
CA2438315C (en) 2014-09-02
TWI335934B (en) 2011-01-11
ATE500316T1 (de) 2011-03-15
CA2438315A1 (en) 2002-09-26
NZ528208A (en) 2008-04-30
TW201040262A (en) 2010-11-16
TWI334884B (en) 2010-12-21
CA2852293A1 (en) 2002-09-26
ES2362041T3 (es) 2011-06-27
US6790950B2 (en) 2004-09-14
WO2002075507A3 (en) 2003-09-12
TWI328035B (en) 2010-08-01
US20040110268A1 (en) 2004-06-10
AU2002240033B2 (en) 2007-11-08
US20050003512A1 (en) 2005-01-06
EP1368456A2 (en) 2003-12-10
TW200916577A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
PE20021008A1 (es) Composiciones para vacuna antibacteriana
Merritt et al. Motility and chemotaxis in Agrobacterium tumefaciens surface attachment and biofilm formation
De Smet et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
Cornells et al. ymoA, a Yersinia enterocolitica chromosomal gene modulating the expression of virulence functions
AR047150A1 (es) Unidades de expresion p ef-tu y uso de las mismas en la regulacion de la transcripcion y expresion de genes
Razin Adherence of pathogenic mycoplasmas to host cells
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
AR047151A1 (es) Unidades de expresion p gro y uso de las mismas en la regulacion de la transcripcion y la expresion de genes
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
AR047152A1 (es) Unidades de expresion psod y uso de las mismas en la regulacion de la transcripcion y la expresion de genes
NZ593220A (en) Immunostimulatory oligonucleotides
US20220305141A1 (en) Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators
Martin et al. Constitutive expression of erythromycin resistance mediated by the ermAM determinant of plasmid pAMβ1 results from deletion of 5′ leader peptide sequences
Pougach et al. CRISPR adaptive immunity systems of prokaryotes
Tashiro et al. Generation of small colony variants in biofilms by Escherichia coli harboring a conjugative F plasmid
US9402889B2 (en) Live, oral vaccine for protection against Shigella dysenteriae serotype 1
BR0006915A (pt) Sequências de nucleotìdios para o gene tal
Beattie et al. Transformation between Haemophilus influenzae and Haemophilus parainfluenzae
Cherepanova et al. DNA inhibits dsRNA-induced secretion of pro-inflammatory cytokines by gingival fibroblasts
AR025410A1 (es) Metodo para preparar una bacteria s. thermophilus resistente al ataque de por lo menos un bacteriofago
AR027762A1 (es) Acidos nucleicos aislados de plasmido pmr2 de micromonospora rosaria y vectores preparados a partir de los mismos
Shishido et al. Correlation of enzyme-induced cleavage sites on negatively superhelical DNA between prokaryotic topoisomerase I and S1 nuclease
Ashwath et al. CRISPR and Antisense RNA Technology: Exploiting Nature’s Tool to Restrain Virulence in Tenacious Pathogens
Figurski et al. Targeted Mutagenesis in the Study of the Tight Adherence (tad) Locus of Aggregatibacter actinomycetemcomitans
Savelkoul et al. Identification of Bordetella avium using the polymerase chain reaction

Legal Events

Date Code Title Description
FX Voluntary withdrawal